CRISPR/Cas9-based SLC12A3 gene knock in: a model for cellular feature analysis in Gitelman syndrome

Key Points

• To evaluate the potential of SLC12A3 gene knock-in as a therapeutic approach for Gitelman syndrome.
• Application of CRISPR/Cas9 technology for gene editing.
• Development of a cellular model for studying gene functions.
• Analysis of cellular features impacted by SLC12A3 expression.
• Successful knock-in of the SLC12A3 gene was achieved.
• Cellular features were significantly altered post-gene editing.
• Indications of SLC12A3's therapeutic potential for managing Gitelman syndrome.